Wedbush Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $181
Goldman Sachs Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $200
Looking Into Ascendis Pharma's Recent Short Interest
A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $153 to $220
BioMarin Pharmaceutical Sues Ascendis Pharma for Patent Infringement in Germany
European Equities Traded in the US as American Depositary Receipts Start Week Lower in Monday Trading
factors that put the rise on are not from a rebound but from news, either way the price is above the price before financial reporting
